Literature DB >> 9303411

Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

N Mor1, A Esfandiari.   

Abstract

The combination of clarithromycin and pyrazinamide was found to be synergistic against Mycobacterium tuberculosis in human macrophages. MICs were four- to eightfold lower for this combination than they were for either drug alone. Clarithromycin and rifampin, however, had only an additive effect.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9303411      PMCID： PMC164062          DOI： 10.1128/AAC.41.9.2035

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

Authors:  J Biehle; S J Cavalieri
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Combined effect of pyrazinamide and ofloxacin within the human macrophage.

Authors:  J A Sbarbaro; M D Iseman; A J Crowle
Journal:  Tuber Lung Dis       Date:  1996-12

3.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

Authors:  K Konno; F M Feldmann; W McDermott
Journal:  Am Rev Respir Dis       Date:  1967-03

Review 4.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

5.  Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages.

Authors:  A J Crowle; J A Sbarbaro; M H May
Journal:  Am Rev Respir Dis       Date:  1986-11

6.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Authors:  J B Bass; L S Farer; P C Hopewell; R O'Brien; R F Jacobs; F Ruben; D E Snider; G Thornton
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

Review 7.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

8.  Clarithromycin is inactive against Mycobacterium tuberculosis.

Authors:  C Truffot-Pernot; N Lounis; J H Grosset; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Authors:  E A Gorzynski; S I Gutman; W Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.

Authors:  S J Cavalieri; J R Biehle; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more
  3 in total

Review 1.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 2.  Drug treatment for tuberculosis during pregnancy: safety considerations.

Authors:  G Bothamley
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 3.  Tuberculosis chemotherapy: current drug delivery approaches.

Authors:  Lisa Claire du Toit; Viness Pillay; Michael Paul Danckwerts
Journal:  Respir Res       Date:  2006-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.